



PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/00, 5/00, 5/02	A1	(11) International Publication Number : WO 00/63358
		(43) International Publication Date : 26 October 2000 (26.10.00)
(21) International Application Number: PCT/US00/08799		(81) Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TI TM TR TT TZ UA US UZ VN YU ZA ZW ARPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 April 2000 (04.04.00)		
(30) Priority Data: 09/292,358 Not furnished		15 April 1999 (15.04.99) US 30 March 2000 (30.03.00) US
(71)(72) Applicant and Inventor: NAIR, Padmanabhan, P. (USCIS); 4520 Hemlock Cone Way, Ellicott City, MD 21042 (US).		
(74) Agent: CHESSER, William, L.; Jones Jain, L.L.P., Suite 800, 1990 M Street, N.W., Washington, DC 20036 (US).		
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NONINVASIVE DETECTION OF COLORECTAL CANCER AND OTHER GASTROINTESTINAL PATHOLOGY

(57) Abstract

A method for isolating viable, biologically substantially pure exfoliated fecal colonocytes at normal ambient temperature is described. Immunocytocytes and inflammatory cells indicative of certain gastrointestinal conditions and a noninvasive method for detecting colorectal cancer are set forth. Composition of transport and suspension media for isolation of colonocytes are detailed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.	
AL	Albania
AM	Armenia
AT	Austria
AU	Australia
AZ	Azerbaijan
BA	Bosnia and Herzegovina
BB	Bahamas
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CC	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CU	Cuba
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finnland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GH	Ghana
CN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IL	Israel
IS	Iceland
IT	Italy
JP	Japan
KZ	Kazakhstan
KG	Kyrgyzstan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KR	Kazakhstan
KR	Saint Lucia
LC	Liechtenstein
LA	Lao PDR
LK	Sri Lanka
LR	Liberia
LT	Lithuania
LV	Lithuania
LV	Lithuania
LV	Lithuania
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
MK	Macedonia
MN	Mongolia
MR	Mauritania
MV	Maldives
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russia
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SV	Senegal
SZ	Switzerland
TG	Togo
TJ	Tajikistan
TM	Turkmenistan
TR	Turkey
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam
YU	Yugoslavia
ZW	Zimbabwe

NONINVASIVE DETECTION OF COLORECTAL CANCER  
AND OTHER GASTROINTESTINAL PATHOLOGY

This is continuation-in-part of pending U.S. application Ser. No. 09/292,358 filed April 15, 1999.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is related to isolated colonocytes enabling early noninvasive detection of colorectal cancer and other gastrointestinal diseases. More particularly, the present invention is related to isolated, biologically substantially pure and viable immunocytocytes and nonepithelial cells of lymphoid origin obtained from a small fecal sample. The invention is further related to providing a transport medium and a dispersion or suspension medium for isolating viable colonocytes from a fecal sample at normal ambient temperature and a method for detecting colorectal and other gastrointestinal pathology employing the isolated colonocytes of the present invention. The isolated colonocytes also allow the study and determination of other anomalous conditions, symptoms, disorders or pathological conditions.

20

PRIOR ART

A common gastrointestinal malignancy in humans is colorectal cancer. It has been estimated that colorectal cancer accounts for approximately 14% of all cancer-related deaths in men and women in the United States and its incidence continues to be high (Boring et al., CA Cancer J. Clin. 1994; 44:7-26). Early detection is a critical factor in successful treatment of this cancer, as it is in the treatment of other malignancies.

Screening approaches to detection of colon and colorectal tumors are presently based on the use of (a) fecal occult blood test (FOBT), (b) flexible sigmoidoscopy, (c) double contrast barium enema, and (d) colonoscopy. Among these screening tests only

FOBT, which is based on a relatively high probability of bleeding from colorectal tumors, is noninvasive, simple and relatively inexpensive. However, frequent false positive and false negative results of the FOBT considerably limit its specificity and sensitivity. Other procedures are expensive and invasive. Hence, there is a clear need for providing a simple, noninvasive, reliable and inexpensive method for detecting colorectal cancer, gastrointestinal (GI) tract diseases and other pathological conditions.

Colonocytes represent an important source of informational marker molecules that provide a picture of the immediate past metabolic history of the GI tract of a subject. In addition, such cells are representative of the cell population from a statistically large sampling frame reflecting the state of the colonic mucosa along the entire length of the colon in a non-invasive manner, in contrast to a limited sampling by colonic biopsy using an invasive procedure involving endoscopy.

Colonocytes undergo certain changes or transformations and carry certain biological or chemical markers indicative of colonic pathologies including precancerous and cancerous conditions. Therefore, the colonocytes could serve as a valuable early indicator of the onset of neoplastic processes and other pathophysiological changes in the GI tract. Subtle changes in the genes and surface proteins are examples of such neoplastic markers. In particular, Ki67, the cell surface glycoprotein CD44 and tumor-associated antigens 19-9 and lectin binding are specific biomarkers of neoplastic transformation in the GI tract. There is also a strong correlation between the amount of DNA in isolated colonic cells and the presence of tumors, because rapidly dividing cells contain more DNA. It is also well recognized that the development of colonic adenomatous polyps and cancer is a multistep process involving activation of oncogenes (ki-ras), inactivation of tumor-suppressor genes (p53 and APC), and alterations in the DNA mismatch repair genes.

Heretofore, it was generally understood in the art to which this invention belongs that exfoliated colonic cells are destroyed once they are shed into the stools, the reason being that these cells start breaking down as soon as they are exposed to the atmosphere. The enzymes, mucus and the bacteria contained in the stool contribute to the process of

destroying the colonic cells. Chilling the freshly collected stool sample to the temperature below -20° C has been described, for example, in U.S. patents #5,094,956, #5,380,647 and #5,455,160 only for preserving the chemical constituents, without regard to the cellular components. Thus, these procedures do not retain cellular integrity and are not applicable for isolating intact, viable cells free of other impurities.

Dutta and Nair (Gastroenterology, 114:1333-1335, 1998) refer to Albaugh et al (Int. J. Cancer, 52:347-350, 1992) and Iyengar et al (FASEB J. 15: 2856-2859, 1991) for accomplishing isolation of viable colonic cells. Albaugh et al described a transport medium and a procedure to obtain colonocytes from a stool sample based on earlier work of Iyengar et al. However, the transport medium of the prior art is different from the transport medium of the present invention in as much as Albaugh et al's medium consisted of a saline solution to which antibiotics were added in addition to fatty acid free BSA. In other words, the prior art transport medium was deficient at least in one criterion, i.e., in not having a mucolytic agent which is an absolute necessity for the formulation of the transport medium in accordance with the present invention.

Furthermore, in Albaugh et al's system the stool sample after collection had to be kept cool in ice while being transported to the laboratory for further processing and could be preserved in ice only for about an hour. In contrast, the system of the present invention does not require cooling in ice and achieves desirable results at the normal ambient temperature which is an important feature of the present invention. Moreover, Albaugh et al state that although their cells had a viability in excess of 80%, the presence of phagocytes and other cells could not be ruled out. Indeed, Figs. 3 and 4 of Iyengar et al clearly show that the cellular preparations obtained were considerably impure. Thus, the procedures of Iyengar et al and Albaugh et al may provide viable colonocytes, but they are inadequate for the purpose of obtaining substantially pure colonocytes. In summary, heretofore it has not been possible to obtain a viable, biologically substantially pure sample of a particular cell type isolated at normal ambient atmospheric conditions from a small fecal mass.

#### SUMMARY OF INVENTION

It is, therefore, an object of the present invention to provide viable, biologically substantially pure exfoliated fecal colonocytes isolated at normal ambient temperature.

It is a further object of the present invention to provide viable, isolated, immunocoprocytes.

It is an additional object of the present invention to provide viable, isolated, inflammatory cells of lymphoid or non-lymphoid lineage.

It is a further object of the present invention to provide a transport medium and a dispersion or suspension medium for isolating viable exfoliated fecal colonocytes at normal ambient temperature.

A further object of the present invention is to provide a noninvasive method for detecting gastrointestinal disorders including colorectal cancer, employing the exfoliated fecal colonocytes isolated at normal ambient temperature in accordance with the teachings of the present invention.

Various other objects and advantages of the present invention will become evident from the detailed description of the invention and from the brief description of the drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, aspects and advantages will be better understood with reference to the drawings in which:

Fig. 1 is a schematic presentation of the process of isolating viable exfoliated colonocytes at normal ambient temperature from a small sample of fecal material;

Fig. 2 presents histogram data from flow cytometry of isolated colonocytes in accordance with the present invention showing a purity greater than 96%; and

Fig. 3 is a diagrammatic representation of classes of colonic cells identified based on their immunoglobulin characteristics.

DETAILED DESCRIPTION OF THE INVENTION

Various objects and advantages of the present invention are achieved by obtaining viable, homogeneous colonocytes of desired cell types isolated from a fecal sample at normal atmospheric conditions and ambient temperature.

5 It should be understood that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the methods and materials described herein are preferred. Unless mentioned otherwise, the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The materials, methods and examples are only exemplary and not limiting.

The term "substantially pure" as used herein means that the product is homogeneous or uniformly of a single type with greater than 96% purity, usually 98%-99% pure, as determined by flow cytometry or by the procedures described herein and is without material interference or contamination of other types of cells.

Herefore, the problem encountered with exfoliated colonocytes in fecal matter was that these cells got destroyed as soon as exposed to the normal atmospheric conditions due to the presence in the fecal matter of proteolytic enzymes, microflora, mucus and the like. Hence, a system had to be devised to inhibit the action of all those factors or elements which prevented the isolation of intact, living colonocytes at normal ambient temperature from fecal matter. This is achieved by the present invention by formulating two different media: (1) a transport medium, and (2) a dispersion or suspension medium. The transport medium is made of physiological saline solution containing an enzyme inactivating amount of an enzyme trapping or protease sequestering agent, a sufficient amount of a bactericidal or bacteriostatic agent to inhibit bacterial activity, and a mucolytic amount of an agent that destroys mucus contained in fecal matter.

Various enzyme trapping, bacteriostatic and mucolytic agents will be suggested to one of ordinary skill in the art and any suitable agents that do not interfere with the objects of the present invention could be used in the formulation of the transport medium in accordance with the teachings of the present invention.

5 Preferred among enzyme trapping agents are proteolytic activity inhibitors and animal proteins. Examples of suitable proteolytic activity inhibitors include PMSF, pepstatin A, bestatin and chymostatin. The reagents that inhibit or deactivate enzymatic activity include formaldehyde, metal chelating agents, heavy metal ions, certain amino acids such as tyrosine and phenylalanine, and high concentrations of zinc or inorganic phosphates. Suitable among animal proteins are those that are non-immune, water soluble compounds including serum albumins of rabbit (RSA), goat (GSA), sheep (SNA), horse (ESA), bovine (BSA) and human (HSA) origin. Certain polyamino acids that do not interfere with a later assay procedure could also be used as enzyme deactivating agents. Suitable examples of such polyamino acids are poly-L-lysine, poly-L-proline, poly-L-tyrosine and the like.

10 Suitable examples of bacteriostatic agents are sodium azide, sodium benzoate, antibiotics (such as penicillin, streptomycin, amphotericin B, gentamicin, polymyxin B and the Like), glycyrrhetic acid, glycyrrhetic acid ( $\alpha$  &  $\beta$ ), suitable derivatives thereof, and the like. A preferred bacteriocidal agent is Thimerosal (Sigma Chemical Co.) and a preferred bacteriostatic agent is glycyrrhetic acid.

15 Suitable examples of mucolytic agents are guafenesin, guaiacol, potassium iodide,  $\beta$ -mercaptoethanol, dithiothreitol, capsaicin, glycyrrhizin and the like. A preferred mucolytic agent is guafenesin (Sigma Chemical Co.).

Puck's Saline G is a preferred source of physiological saline solution.

20 A preferred transport medium is prepared as follows:

Puck's Saline G	500 ml
Sodium Bicarbonate	350 to 500 mgs
BSA	2.5 to 15 gms
Guafenesin	2.5 to 5 gms

Glycyrhizic acid 2 to 4 gms

The dispersion or suspension medium differs from the transport medium with respect to bacteriocidal/bacteriostatic agent, e.g., glycyrrhizic acid, which is omitted when preparing the dispersion or suspension medium.

PROCEDURE FOR ISOLATING SUBSTANTIALLY PURE COLONOCYTES AT NORMAL AMBIENT TEMPERATURE:

Referring now to Fig. 1, a small stool sample 10 (about 0.5–1.0 gm) is placed into a tube 11 containing a transport medium and a few glass beads 12, after which the tube is closed with a stopper. The stool sample 10 is then thoroughly dispersed in medium 12, for example by vortexing, after which the contents of tube 11 are filtered through a mesh screen (about 300 µm pore size) into a new tube 13 (a 50 ml polypropylene or similar conical centrifuge tube) and underlaid with a heavy medium 14 having a density in the range of about 1.033 to about 1.25 and centrifuged at about 200 X g for about 10 minutes in a table top centrifuge with the brakes off.

The colonic cells accumulate in the heavy cushion and at the bottom of the tube as a pellet, and are recovered by sucking out with a plastic transfer pipette 15 after removing a band of lighter cells (minor component) 17 at the interface between the heavy medium 14 and the lighter suspension above 18. The cells recovered from the heavy medium and pellet are placed in a new 50 ml centrifuge tube 19 and diluted with about 40 ml of the suspension medium 20. The suspension of cells thus obtained is then centrifuged at about 900 X g for about 10 minutes after which the clear supernatant is discarded and the cell pellet 21 remaining at the bottom of the centrifuge tube is resuspended in phosphate buffered saline (PBS) containing about 1% bovine serum albumin (BSA). The band of lighter cells (minor component) 17 is placed in a second fresh 50 ml centrifuge tube 22 and washed as described for the cells from the heavy cushion and pellet. The cell pellet 21, comprising substantially biologically pure isolated

exfoliated viable colonocytes, is recovered and dispersed in a suitable salt solution (e.g., PBS) and filtered through a 45 µm screen filter..

For determining the viability of the isolated colonocytes, a portion of the pellet 21 is dispersed in PBS/BSA medium 26 (1 ml/gm of stool sample). Then, a 1/10 dilution of the suspension is counted in a hemocytometer in the presence of trypan blue.

As is well known to a skilled artisan, the cells that do not take up trypan blue are considered to be viable and counted to determine the cell yield.

The tube or vial may be made of any suitable material including plastics, polystyrene, polypropylene and the like.

It is important to note that an inventive aspect of the present invention is the formulation of a transport medium and a dispersion or suspension medium which together allow the exfoliated colonocytes found in the fecal sample to remain viable at the normal ambient temperature during and after the isolation procedure. In other words, the invention enables isolation of intact, living exfoliated colonocytes from a small sample (e.g., 0.5–1.0 gm) of fecal material without chilling or freezing, at normal ambient temperature ranging from about 22°C to about 25°C during the entire isolation process. About 8 to 10 million living colonic cells can be obtained from one gram of the stool sample in accordance with the techniques of the present invention.

When maintained at the normal ambient temperature in the suspension medium of the present invention, the isolated colonocytes can be viably preserved for extended periods. Table 1 shows cell yields and viability as a function of storage time and temperature conditions.

Of course, alternate techniques could be substituted in the isolation steps. For example, the suspension of the stool sample in the transport medium 12 may be filtered through screens (149 micrometers, 105 micrometers and 52 micrometers). Also, the pellet in the dispersion medium can be gently overlaid on higher density Percoll gradients and centrifuged so that the cells can be recovered from the top of the gradient. Such modifications are common in the art and are included within the purview of this invention.

It is understood, of course, that whenever appropriate a reference or base line would be usually established using colonocytes obtained from disease-free subjects so that a comparative, diagnostic or evaluation study could be made with colonocytes obtained from a subject suspected of a disease or pathological condition.

5 It was discovered that an important and advantageous feature of the non-invasively obtained colonocytes of the present invention is that these isolated colonic cells carry markers or transformations characteristic of the pathology of the GI tract and, therefore, they can serve as diagnostic and predictor indicators of the GI tract pathology.

## 10 IMMUNOCYTOPHORETIC

Since the colonic cells isolated from stools were discovered to be true representative of the anatomical and pathophysiological condition of the entire colon, among other utilities these cells also allow monitoring of mucosal immunity. The mucosa of the GI tract is a major site for the elaboration of immunological defenses mediated by immunoglobulins. It was discovered that a functionally distinctive group of cells, designated herein as immunocytocytes, can be identified and isolated from the exfoliated cells obtained by the methodologies of the present invention. Immunocytocytes are unique in expressing a specific immunoglobulin designated herein as IgC which is defined as a chimeric immunoglobulin that is recognized by antibodies both to IgG and IgA. Furthermore, immunocytocytes are clonal, antigen-specific and characterized by the presence of Fc receptors and immunoglobulin A (Ig A).

Given the affinity of immunocytocytes to IgG and IgA antibodies, several approaches to isolate the immunocytocytes would be suggested to one of ordinary skill in the art. For example, selective isolation of immunocytocytes from a mixture of cells obtained from stools, colonic purges or washings, or from surgical and autopsy specimens can be achieved using anti-IgG or a specific anti-IgC monoclonal antibody. The indirect immune adherence approach utilizes a panning technique to allow these cells to adhere to petri dishes coated with anti-IgG or specific anti-IgC antibodies. The

use of anti-IgG antibody as a capture agent for immunocytocytes is based on the discovery in accordance with the present invention that pure IgG expressing mono-specific (viz., lacking co-expression of IgA) colonic cells are not detected under normal conditions. Preparation of desired types of monoclonal antibodies are well known to one of ordinary skill in the art and are routinely obtained.

Another approach to obtaining substantially pure immunocytocytes is the use of fluorescence-activated cell sorting (FACS) technique employing fluorochrome-conjugated anti-IgG or Anti-IgC. In one embodiment, colonic cells are incubated with FITC (fluorescein isothiocyanate) labeled IgG, the excess reagent is washed off and the fluorescently-tagged immunocytocytes are sorted in a fluorescence-activated cell sorter.

In another embodiment, monoclonal antibodies to IgG or IgC is covalently or non-covalently attached to a solid matrix, such as agarose beads, glass beads, polystyrene beads, hollow fiber, magnetic beads, plastic tissue culture dishes and the like well known to a skilled artisan. Cells that adhere to the antibody coated support are separated from the cell suspension by simply separating the matrix from the suspension by mechanical, magnetic or any other suitable means. As it would be known to one of ordinary skill in the art, the immunocytocytes can also be bound to the surface of tissue culture flasks coated with anti-IgG or anti-IgC through a linker and after incubating the colonic cell suspension in the flasks, unbound non-immunocytocytes are decanted off. Bound immunocytocytes are then recovered by scraping or by appropriate enzymatic cleavage of the linker. Linkers bound to bead matrices (e.g., sepharose) are commercially available (e.g. Pharmacia).

Two-color immunofluorescent flow cytometry is used to determine the number or population of the immunocytocytes. Colonocytes are incubated with anti-IgG FITC (green fluorescence) and anti-IgA PE (phycoerythrin, red fluorescence). After washing the cells with a buffer to remove the excess antibodies, the cells are then analyzed in a flow cytometer to count the cells with single fluorescence (green or red) and those cells with double fluorescence (both green and red). Cells with double fluorescence are the

5 10 15 20 25

chimeric IgC immunocytocytes, while cells with the red fluorescence are IgA secreting colonic epithelial cells. In most colonic preparations from normal subjects, there is no measurable number of cells recognizing only anti-IgG FITC. In other words, colonocytes bearing only IgG are rare and may be associated with abnormal mucosal or systemic immune dysfunction when they are present.

Analyses of immunofluorescently labeled cells by flow cytometry have revealed the existence of at least three types of colonocytes. To distinguish the Fc receptor of immunocytocytes from other Fc receptors, the Fc receptor of immunocytocytes has been designated herein as CFc receptor. Table 2 shows some representative normal distribution of IgC, CFC and IgA found in these cells. A deviation from the normal values would indicate a disease process involving the immune system. Figure 3 is a diagrammatic representation of at least three types of colonocytes generally detected:

10 "A" shows immunocytocytes with several unique chimeric immunoglobulin IgC represented by two antibody binding sites on each molecule 2 and several CFC receptors 3. "B" shows colonocytes similar to "A", but with several IgA immunoglobulin molecules 5 along with several CFC receptors 3. "C" shows colonocytes similar to "A" and "B", but with no immunoglobulin and only CFC receptors.

15 Immunocytocytes, IgA bearing colonocytes and CFC receptor bearing colonocytes described above have distinct roles in immune surveillance of the GI tract and in maintaining systemic humoral immunity of the total organism. These cells perform vital functions: (i) maintaining a balance in the colonization of the colon by microflora; (ii) they are clonal and contain a population of pluripotent cells each one recognizing a single antigen, soluble or particulate, of dietary or biological origin; (iii) they may act as antigen presenting cells to gut-associated lymphoid tissue; (iv) they can be sentinels for detecting invasion by pathogens (e.g., rotavirus, shigella, polio, intestinal parasites, mycobacteria and the like); and (v) their absence can signify a state of immunologic energy of iatrogenic origin or congenital immunoglobulin deficiencies. Because these colonocytes including the immunocytocytes, are antigen-specific, they can be immortalized by transformation with carcinogens, oncogene DNA, EBV, SV-40

and the like, to produce antibody-secreting cell lines specific for the selected antigen by hybridoma technology well known to one of ordinary skill in the art.

The following examples illustrate specific utilities of the identified or isolated colonocytes of the present invention. These examples are only illustrative and not limiting in any manner.

EXAMPLE - 1

Colonic cells isolated from normal subjects by the procedures described in the present invention are substantially free of any inflammatory cells. In inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, a significant number of inflammatory cells are mobilized to the surface of the colonic mucosa and are exfoliated along with cells of the epithelium.

One to two gram aliquots of stool collected from IBD patients, suspended in the transport medium are homogenized in a Stomacher with about 150 ml of suspension medium. Aliquots (30 ml) of the suspension are underlaid with 10 ml of Histopaque 1077 (density of 1.077) and centrifuged at room temperature at 200 X g for 30 minutes with the brakes off. The interface between the aqueous suspension and the Histopaque 1077 is recovered and washed three times by repeated centrifugation. In this process, inflammatory cells are recovered in addition to the normal complement of colonic cells.

20 The inflammatory cells in the mixture of cells are tagged with anti-CD45/FITC (green fluorescence) and the positive cells are counted in a flow cytometer. CD45 (cluster of differentiation) also known as leucocyte common antigen, is a lineage-specific marker for lymphoid cells and are present on inflammatory cells. In addition a second marker of inflammation, anti-COX-2/PE (red fluorescence) may also be employed to detect inflammatory cells. Since colonic epithelial cells are negative for CD45, the number of CD45 positive cells in an isolate is a direct measure of the severity of the inflammatory process in IBD. Monitoring of cells positive for both CD45 and COX-2 is an extremely useful non-invasive procedure for following the progression of the disease during the course of treatment.

are useful in DNA typing and examination of biological macromolecules (such as DNA, RNA, protein and the like) for determining responses, for example, to pharmacologic and environmental agents and assessment of multi-drug resistance. These isolated cells are also useful in various other ways easily suggested to a skilled artisan.

It should be apparent that given the guidance, illustrations and examples provided herein, various alternate embodiments, modifications or manipulations of the present invention would be suggested to a skilled artisan and these are included within the spirit and purview of this application and scope of the appended claims.

EXAMPLE - 2

ASSESSMENT OF STATUS OF MUCOSAL IMMUNITY:

Cells are obtained as described above from subjects who are suspected of having an immunocompromised gut. Aliquots of cells (about 110K) are suspended in PBS buffer and incubated at 37° C for about 45 minutes with one of the following combinations of fluorescently labeled antibodies: anti-IgG FITC (green) anti-IgA PE (red), and anti-IgC FITC + anti IgA PE. A parallel tube containing cells with an isotype control antibody is also maintained to account for nonspecific binding antibody. Direct immunofluorescence assays are conducted to measure the binding of antibodies to different sets of colonic cells. A significant decrease in number of immunocoproctes (expressing IgC) or IgA bearing cells is of diagnostic significance for immune deficiency. Table 2 lists values obtained for normal subjects. Any deviation from the normal values would be indicative of immune dysfunction. It should be noted that direct and indirect immunofluorescence assays can be similarly carried out for the assessment of a repertoire of macromolecules, such as cytokines, signal transduction intermediates, growth factors and the like.

EXAMPLE - 3

EXPRESSION OF COLON CANCER-ASSOCIATED BIOMARKERS:

Cells are obtained as described above from patients suspected of having colon cancer or precursors of colon cancer (polyps). In one embodiment of this technique, cells are subjected to indirect immunofluorescence assay for the expression of CD44 or its molecular variants, e.g., CD44V3, CD44V6 and CD44V10; the presence of CD44 or its molecular variants being diagnostic of colon cancer.

EXAMPLE - 4

As a source of somatic cells obtainable non-invasively, the colonocytes of the present invention are representative of the phenotype as well as genotype. Thus, they

Table 1. Effect of Storage on Cell Yields

Storage Time	Conditions	Cell Yield %	Viability %
1 - 6 Hrs	Ambient	100	85+
3 days	Ambient	135	85+
3 days	4°C	70.2	85+
8 days	Ambient	97.5	80+
8 days	4°C	142	75+

Table 2. Distribution of IgC, IgA and CFc bearing colonic cells

Subject Code	IgC	CFc Receptor	IgA
308-S1	18.5	90.3	46.5
308-S2	20.8	87.8	42.0
318-S1	12.2	86.9	47.7
318-S2	26.5	91.2	37.7
319-S1	27.5	88.9	44.0
319-S2	32.9	90.9	30.0
321-S1	20.2	88.9	40.0
321-S2	16.8	82.2	24.0

Note: The numbers represent the % of total cells that carry the corresponding molecule. These results were obtained by flow cytometric analysis of immunofluorescently labelled colonic cells isolated by the technology described in this application.

1      1      1      1      1      1      1      1      1  
9.      The colonocytes of claim 1 expressing only CFc.

CLAIMS

Having thus described our invention, what we claim as new and desire to secure by Letters Patent is as follows:

1. Viable, biologically substantially pure exfoliated fecal colonocytes isolated at normal ambient temperature.
2. The colonocytes of claim 1 bearing a marker indicative of specific gastrointestinal condition.
3. The colonocytes of claim 2 bearing a marker indicative of neoplastic transformation.
4. The colonocytes of claim 2 bearing a marker indicative of immune dysfunction.
5. The colonocytes of claim 2 showing abnormality indicative of non-neoplastic gastrointestinal pathology.
6. The colonocytes of claim 1 being epithelial or nonepithelial cells of lymphoid origin.
7. The colonocytes of claim 1 expressing a chimeric immunoglobulin IgC.
8. The colonocytes of claim 1 expressing only IgA and CFc.
9. The colonocytes of claim 1 expressing only CFc.

- 1        10. A transport medium for collecting a fecal sample, comprising:
  - 2            (a) a sufficient amount of an agent to sequester
  - 3            proteases present in fecal matter;
  - 4            (b) a sufficient amount of a mucolytic agent to destroy mucus
  - 5            present in fecal matter; and
  - 6            (c) a sufficient amount of a bacteriocidal agent to inhibit bacterial
  - 7            activity in fecal matter.
- 1        11. The transport medium of claim 10, wherein said agent for sequestering
- 2            proteases is selected from the group consisting of plasma proteins, gel
- 3            forming polymers and synthetic resins.
- 1        12. The transport medium of claim 11, wherein said plasma proteins are
- 2            bovine serum albumin, egg albumin or human serum albumin.
- 1        13. The transport medium of claim 12, wherein the mucolytic agent is
- 2            selected from the group consisting of N-acetyl cysteine,  $\beta$ -
- 3            mercaptoethanol, capsaicin, dithiothreitol, guaiacol and guafenesin.
- 1        14. The transport medium of claim 13, wherein the bacteriocidal agent is
- 2            selected from the group consisting of thimerosal, antibiotics, sodium
- 3            azide, glycyrrhetic acid and glycyrrhetic acid ( $\alpha$  &  $\beta$ ).
- 1        15. The transport medium of claim 14 being a solution, comprising:
  - 2            sodium bicarbonate: 350-500 mg;
  - 3            bovine serum albumin: 2.5-15 gms;
  - 4            Guafenesin 2.5-5.0 gms;
  - 5            Glycerrhizic acid 2.0-4.0 gms; and
  - 6            Puck's Saline G: 500 ml.
- 1        16. The transport medium of claim 15 being devoid of glycyrrhetic acid,
- 2            thereby said transport medium transforming into a dispersion or
- 3            suspension medium.
- 1        17. A method for isolating biologically substantially pure exfoliated fecal
- 2            colonocytes at normal ambient temperature, comprising the steps of:
  - 3            (a) collecting a fecal sample in a transport medium maintained
  - 4            at normal ambient temperature;
  - 5            (b) dispersing the fecal sample in said transport medium diluted
  - 6            with a suspension medium;
  - 7            (c) sedimenting cells present in the diluted transport medium of
  - 8            step (b) to isolate the cells from impurities by layering the
  - 9            cell suspension over a medium of heavier density;
  - 10          (d) subjecting the cells in step (c) to an influence resulting in
  - 11          the formation of a cellular band at a boundary with said
  - 12          heavier medium and forming cellular fractions within the
  - 13          heavier medium and peller; then
  - 14          (e) recovering biologically substantially pure colonocytes from
  - 15          said cellular band and from the heavier medium and the
  - 16          pellet.
- 1        18. The method of claim 17, wherein said heavier medium is of density
- 2            ranging from about 1.033 to about 1.25.
- 1        19. The method of claim 18, wherein said heavier medium is of density 1.25.
- 1        20. A method for detecting colorectal cancer, comprising the steps of:
  - 2            (a) obtaining biologically substantially pure colonocytes; then

(b) reacting said colonocytes with a reagent to detect the presence of a marker determinative of cancer, occurrence of a positive reaction of said colonocytes with said reagent being indicative of the presence of cancer.

21. The method of claim 20, wherein said reagent is fluorescently labeled  
antibodies or plant lectins that generate a colored product.

22. A method for determining mucosal immunity of GI tract, comprising the  
step of comparing the number of immunocoprocytes recovered from a  
subject whose GI tract mucosal immunity is to be determined, with the  
number of immunocoprocytes recovered from a normal subject, a  
statistically significant deviation from normal value being indicative of  
the level of immune dysfunction.

1           2           3           4

23. A method for diagnosing GI tract pathology, comprising the step of  
determining the presence of inflammatory cells in a stool sample of a  
subject suspected of GI tract pathology, the presence of inflammatory  
cells being indicative of GI tract pathology.

1           2           3           4

25. A method of producing antigen-specific monoclonal antibodies,  
comprising the step of employing antigen-specific immunocytocytes as a  
clone in a standard hybridoma technique and recovering antigenspecific  
monoclonal antibodies.





Fig. 1. Schematic representation of the steps in the isolation of viable, substantially pure colonocytes.



## Histogram Statistics

File: E3RN.001  
 Log Data Units: Linear Values  
 Patient ID:  
 Sample ID: colonic cells  
 Tube:  
 Panel:  
 Date: G3  
 Total Events: 1469  
 X Parameter: FL1-H (Log)

Marker Left	Right	Events	% Gated	Total	Mean	Geo Mean	CV	Median	Peak Ch
All	1, 8910	1469	100.00	14.69	36.30	20.00	179.56	18.11	11
M1	1, 165	1418	98.53	14.18	26.09	18.15	97.70	17.00	11
M2	165, 8910	52	3.54	0.52	317.38	293.10	45.83	278.81	198

Fig. 2 Histogram data from flow cytometry of isolated colonocytes in accordance with the procedure of the present invention showing a purity of 96.5%. The numbers in the abscissa represent the size distribution of the cells. The numbers in the ordinate represent cell counts. M1 represents the single peak detected by the flow cytometer and M2 indicates the residual impurity.




Fig. 3 Diagrammatic representation of classes of immunocytocytes identified on the basis of their immunoglobulin characteristics. A: Immunocytocytes coexpressing chimeric IgC and CFC receptors. B: Immunocytocytes coexpressing IgA and CFC receptors. C: Immunocytocytes expressing only CFC receptors.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/08799

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00, 5/00, 5/02  
US CL : 435/172.2, 325, 803, 804

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
Agricola, BIOSIS, BIOTECHBASE, BIOSCIENCE, CANCERLIT, CAPLUS, CONFSCI, DDFU, DRUGU, ENBASE, LIFESCI MEDLINE, SCISEARCH, TOXIT

Search terms: coloncysts, isolate, purify, focal, focus

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
AGRICOLA, BIOSIS, BIOTECHBASE, BIOSCIENCE, CANCERLIT, CAPLUS, CONFSCI, DDFU, DRUGU, ENBASE, LIFESCI MEDLINE, SCISEARCH, TOXIT

search terms: coloncysts, isolate, purify, focal, focus

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

## Category\* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X DUTTA et al. Noninvasive detection of Colorectal Cancer by Molecular Tools: Coming of Age. Gastroenterology, June 1998, Vol. 114, No. 6, pages 1333-1335, see especially page 1333, col. 1, and page 1334 col. 1. 1, 2-6, 20-21

X ALBAUGH et al. Isolation of Exfoliated Colonic Epithelial Cells, A Novel, Non-Invasive Approach to the Study of Cellular Markers. Int. J. Cancer, 1992, Vol. 52, pages 347-350, see especially abstract and Materials and Methods, page 347, cols. 1 and 2. 1-6, 17-21

Further documents are listed in the continuation of Box C.  See patent family annex.

Special categories of cited documents:

\*X\* document defining the earliest date of the art which is not considered to be of particular relevance. "T" later documents published after the international filing date, but prior to the principle or theory underlying the invention

\*E\* earlier document published on or after the international filing date of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*L\* document which may show doubts on priority since(s) or which is cited to establish the publication date of another document or which is special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed. "a" document in a member of the same patent family

Date of the actual compilation of the international search

17 JULY 2000

Date of mailing of the international search report

15 AUG 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3200

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/08799

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
X	IYENGAR et al. Human stools as a source of viable colonic epithelial cells. FASEB J. October 1991, Vol. 5, pages 2856-2859, see especially Abstract and Materials and Methods section, page 2856, col. 2 and page 2857, col. 1. 1, 17-19

Form PCT/ISA/210 (continuation of second sheet) (July 1998)\*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08799

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(e) for the following reasons:

1.  Claims No.:  
because they relate to subject matter not required to be searched by this Authority, namely:

2.  Claims No.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  Claims No.:  
because they are dependent claims and are not drafted in accordance with the second and third sentence of Rule 6(4).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extr Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-9 and 17-21

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08799

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not to be linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fee must be paid.

Group I, claim(s) 1-9 and 17-21, drawn to a method of making and using focal colonies.

Group II, claim(s) 10-16, drawn to a transport medium.

Group III, claim(s) 22, drawn to a method for determining mucosal immunity.

Group IV, claim(s) 23-24, drawn to a method of diagnosing GI tract pathology.

Group V, claim(s) 25, drawn to a method of producing antibodies.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of invention because they are not to be linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fee must be paid. The species are as follows:

Group Ia drawn to colonies expressing chimeric IgC, claim 7.

Group Ib drawn to colonies expressing only IgA and CFC, claim 8.

Group Ic drawn to colonies expressing only CFC, claim 9.

Group IIa drawn to an agent for sequestering proteases, plasma proteins, claim 11.

Group IIb drawn to an agent for sequestering proteases, gel forming polymers, claim 11.

Group IIc drawn to an agent for sequestering proteases, synthetic resins, claim 11.

Group Id drawn to a mucolytic agent, N-acetyl cysteine, claim 13.

Group IIe drawn to a mucolytic agent, beta mercaptoethanol, claim 13.

Group IIff drawn to a mucolytic agent, capsaicin, claim 13.

Group IIgg drawn to a mucolytic agent, dithiothreitol, claim 13.

Group IIhh drawn to a mucolytic agent, guaiacol, claim 13.

Group IIii drawn to a mucolytic agent, guiflufenain, claim 13.

Group IIjj drawn to a bacteriocidal agent, thimerosal, claim 14.

Group IIkk drawn to a bacteriocidal agent, antibiotics, claim 14.

Group IIll drawn to a bacteriocidal agent, sodium azide, claim 14.

Group IIim drawn to a bacteriocidal agent, glycyrrhetic acid, claim 14.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

An application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, (see PCT article 7(3) (a) and 1.476 (c), 37 C.F.R. 1.475(d)). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d)).

Group I is drawn to a product, a method of making that product and a method of using that product and therefore have unity of invention.

Groups III-V are drawn to different methods of using said product.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

Each of the agents claimed are used in materially distinct methods which differ at least in objectives, method steps, reagents and/or dosage and/or schedule used, response variables, and criteria for success.